Way back in 1995, 15-year-old GT Dave began brewing his first batch of kombucha in his childhood home. Flash forward 30 years, and what was once, for American consumers, an obscure, fermented Asian tea drink is now a multimillion dollar beverage category with a presence in just about every major retail channel across the United States.
GT’s Living Foods announced this week the formation of a Science Advisory Board (SAB) which will consult the kombucha maker on health and science-based research. According to GT’s founder and CEO GT Dave, the board will not only advise the company, but also communicate directly with consumers, including sharing information and up-to-date research on kombucha’s impact on overall health and wellness.
Though preventative medicine is routinely of consumer interest, the onset of the coronavirus has made immune support a hot topic, particularly as no treatment, cure or vaccine currently exists. Until they are found, supporting a healthy immune system is seen– and shopped — widely as one of the ways individuals can be proactive in the fight against the virus.
